Panel Disdussion

More documents

Recommendations

Info

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of Nuclear Congress Medicine of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011 Simulation of Msgc using two methods: Monte carlo and Finite difference method Kokab moosavi Nuclear Science and Technology Research Institute Micro Strip Gas Chambers (MSGCs) are suited for the application in modern experiments of high energy physics because of their good spatial resolution and their high rate capability. In this work msgc was simulated by using two methods: Monte Carlo and Finite Difference Method. The electric field variations versus different anode and cathode widths and cathode to anode distance studied and at least the number of particles entered on anode and the deposited energy in the region of electric field lines were calculated. This chamber could be useful in medical imaging systems because of excellent position resolution. Keywords: MSGC, simulation, electric field 158
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of Congress of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011 Development of an in vivo radionuclide generator by labeling Bleomycin with 191Os Leila Moghaddam-Banaem 1 , Amir Reza Jalilian 1 , Mina Jamreh 2 , Nafiseh Salek 2 , Mojtaba Shamsaee 2 1 Radiopharmaceutical Research and Development Lab (RRDL) 2 Faculty of Nuclear Engineering and Physics-AmirKabir Technical University Bleomycin (BLM) has been labeled with various radioisotopes and widely used in therapy and diagnosis. 191Osmium is a parent radionuclide with 15.4d half-life and decays by beta emission to 191mIridium which is a radionuclide with 4.96s half-life. It decays by isometric transition to stable 191Ir, emitting a 129-keV gamma photon. In this study BLM was labeled with 191Os-hexachloro-osmate and its distribution and stability in mice was determined. The complex was obtained at the pH=2 in normal saline at 90°C in 60 minutes. Radio-TLC showed an overall radiochemical yield of 95-97% (radiochemical purity >97%). The biodistribution studies for 191Os and 191Os -BLM were carried out in mice up to 15d. Liver and spleen uptake increased 24-48 hours after administration of 191Os-BLM. Lung uptake increased after 48 hours. Twenty four hours after administration, the radioactivity of the bladder and kidney increased and remained constant. This research introduces 191Os-BLM in therapeutic studies as an in-vivo generator for therapy because of beta emissions and also for localization and dosimetry study in relevant organs by gamma emission of the daughter radio-nuclide. Keywords: 191Osmium-Bleomycin, Labeling, Biodistribution 159
Page 1 and 2:
3rd International Congress of Nucle
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
3rd International Congress of of Nu
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108: 3rd International Congress of of Nu
Page 157: 3rd International Congress of of Nu
show all

Panel Disdussion

Create successful ePaper yourself

Delete template?

Save as template?